| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Community Consortium, Positive Health Program (D.I.A., S.B.S., H.V., M.E.K.), Hematology-Oncology (D.I.A., M.E.K.), and Neurology (C.A.J.), Divisions at San Francisco General Hospital; and Departments of Medicine (D.I.A., S.B.S., H.V., M.E.K.) and Neurology (C.A.J., H.R., S.P., M.C.R., K.L.P.), and the UCSF Pain Clinical Research Center (H.R., S.P., M.C.R., K.L.P.), University of California San Francisco.
Address correspondence and reprint requests to Dr. Donald I. Abrams, San Francisco General Hospital, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110; e-mail: dabrams{at}php.ucsf.edu
Objective: To determine the effect of smoked cannabis on the neuropathic pain of HIV-associated sensory neuropathy and an experimental pain model.
Methods: Prospective randomized placebo-controlled trial conducted in the inpatient General Clinical Research Center between May 2003 and May 2005 involving adults with painful HIV-associated sensory neuropathy. Patients were randomly assigned to smoke either cannabis (3.56% tetrahydrocannabinol) or identical placebo cigarettes with the cannabinoids extracted three times daily for 5 days. Primary outcome measures included ratings of chronic pain and the percentage achieving >30% reduction in pain intensity. Acute analgesic and anti-hyperalgesic effects of smoked cannabis were assessed using a cutaneous heat stimulation procedure and the heat/capsaicin sensitization model.
Results: Fifty patients completed the entire trial. Smoked cannabis reduced daily pain by 34% (median reduction; IQR = –71, –16) vs 17% (IQR = –29, 8) with placebo (p = 0.03). Greater than 30% reduction in pain was reported by 52% in the cannabis group and by 24% in the placebo group (p = 0.04). The first cannabis cigarette reduced chronic pain by a median of 72% vs 15% with placebo (p < 0.001). Cannabis reduced experimentally induced hyperalgesia to both brush and von Frey hair stimuli (p 
0.05) but appeared to have little effect on the painfulness of noxious heat stimulation. No serious adverse events were reported.
Conclusion: Smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain from HIV-associated sensory neuropathy. The findings are comparable to oral drugs used for chronic neuropathic pain.
Supported by the University of California Center for Medicinal Cannabis Research and NIH Grant 5-MO1-RR00083. Dr. Rowbotham received support from NINDS K24 NS02164.
Disclosure: The authors report no conflicts of interest.
Received August 1, 2006. Accepted in final form October 30, 2006.
Related Article
Neurology 2007 68: 478-479.
This article has been cited by other articles:
|
|
 |
|
  T. Wang MSc, J.-P. Collet PhD MD, S. Shapiro PhD, and M. A. Ware MBBS MSc Adverse effects of medical cannabinoids: a systematic review Can. Med. Assoc. J., June 17, 2008; 178(13): 1669 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Simpson, S. Brown, J. Tobias, and For the NGX-4010 C107 Study Group Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy Neurology, June 10, 2008; 70(24): 2305 - 2313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P Cohen Cannabinoids for chronic pain BMJ, January 26, 2008; 336(7637): 167 - 168. [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. J. Wallace, J. Blackbeard, A. R. Segerdahl, F. Hasnie, T. Pheby, S. B. McMahon, and A. S. C. Rice Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain Brain, October 1, 2007; 130(10): 2688 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Marijuana for Painful Peripheral Neuropathy? AIDS Clinical Care, April 30, 2007; 2007(430): 1 - 1. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
